GSK Malaysia recalls one batch of Zyrtec-D tablets

KUALA LUMPUR: GlaxoSmithKline Malaysia (GSK) has recalled its Zyrtec-D (120mg/5mg Tablets x400) Allergy Relief and Nasal Decongestant Tablets batch number 321907 with the expiry date January 2025 printed on the blister pack.

GSK, in a statement Thursday (March 30), said that the decision to recall the product is a precautionary measure after some units were found to have blisters that were incorrectly sealed.

“All tablet packs and/or blisters from this batch are being recalled at all levels in the Malaysian market, including those already dispensed to patients.

“GSK is requesting all patients who have been dispensed Zyrtec-D tablets from any in-country retail, pharmacy or healthcare outlet to return the product with immediate effect to the original point of purchase, within the next 15 days,” read the statement.

GSK also urged all healthcare professionals to immediately cease prescribing, dispensing, selling, or distributing product from this batch, while patients should seek advice from their healthcare provider on alternative treatments.

GSK added that at present, there is no evidence that any other batches are affected, and no other complaints have been received about this product from any market since 2018.

The company added that the recall does not affect Zyrtec Drop 10mg/ml, Zyrtec Solution 1mg/ml and Zyrtec Tablet 10mg, and patients may continue these medications.

Consumers or healthcare providers with questions regarding this recall may contact GSK at +603-7495 2600 on Monday to Friday from 9am to 5pm, or by e-mail at [email protected].

“Patients who have been prescribed and dispensed products from this batch and have concerns should contact their healthcare provider first.

“Pharmacies, clinics and hospitals that have recalled products to be returned, please contact Zuellig Pharma Sdn Bhd at 1-800 88 1388 or email [email protected].

“Any matter related to Human Safety Information/ Adverse Event, please contact GSK Pharmacovigilance via email at [email protected],” the statement added.

Source: The Star


Leave a Reply

Your email address will not be published. Required fields are marked *

Read more

Related Posts